体内研究 (In Vivo) |
Hyaluronan-IN-1 (40 mg/kg;腹腔注射;每周 2 次;持续 5 周) 会抑制野生型及 CD44-/- 小鼠断奶后的正常肠道与结肠生长,降低上皮细胞增殖水平并减轻体重,但对 TLR4-/- 小鼠无上述作用,表明该效应依赖于 TLR4 信号通路。 Hyaluronan-IN-1 (40 mg/kg;腹腔注射;每隔 1 天给 1 次;共 7 天) 可减少野生型及 CD44-/- 新生小鼠的隐窝裂变,抑制 Lgr5+ 干细胞增殖,抑制隐窝基底上皮细胞增殖,促进细胞凋亡并减少潘氏细胞数量,但对 TLR4-/- 小鼠无上述作用,表明这些新生小鼠肠道发育相关作用依赖于 TLR4 信号通路。 Hyaluronan-IN-1 (每耳 13.3-40 µg;皮下注射;单次或两次;DNFB 暴露前 1-3 天) 可呈剂量和时间依赖性地抑制半抗原诱导的小鼠表皮朗格汉斯细胞迁移,在 DNFB 暴露前 24 h 和 1 h 分别给予每耳 40 µg 的两次注射可实现完全抑制。 Hyaluronan-IN-1 (每耳每次注射 40 µg;皮下注射;共注射 2 次;致敏前 24 h 和 1 h 给药) 可在局部和时间上抑制小鼠接触性超敏反应的致敏阶段,且不会诱导长期无反应性。 Hyaluronan-IN-1 (每耳 40 µg-每只动物 1 mg;皮下注射、静脉注射、局部;单次或两次注射;激发前 1-24 h) 可抑制小鼠急性接触性超敏反应的诱导阶段,减轻耳肿胀、水肿及白细胞浸润。 Hyaluronan-IN-1 (每耳每次注射 40 µg;于第 0、1、3、5 天给) 可显著抑制由半抗原反复涂抹诱导的小鼠慢性皮炎。 Hyaluronan-IN-1 (每只小鼠 500 μg;静脉注射;单次联合注射) 可显著降低雌性 C57BL/6 小鼠中 B16-F10 黑色素瘤的肺转移发生率并延长生存期,肿瘤接种后 48 天的存活率为 35.1%。
| Animal Model: |
C57BL/6J (male, wild-type, CD44-/-, TLR4-/-, 3 weeks old at study start) |
| Dosage: |
40 mg/kg |
| Administration: |
i.p.; twice a week; 5 weeks |
| Result: |
Reduced small intestinal length, reduced colonic length, decreased jejunal villus height, decreased jejunal crypt depth, decreased colonic crypt depth, reduced number of BrdU-positive epithelial cells per proximal jejunum crypt section, reduced number of BrdU-positive epithelial cells per distal colon crypt section, and lowered average body weight by 10% compared to controls in wild-type mice. Reduced small intestinal length, reduced colonic length, decreased jejunal villus height, decreased jejunal crypt depth, decreased colonic crypt depth, reduced number of BrdU-positive epithelial cells per proximal jejunum crypt section, reduced number of BrdU-positive epithelial cells per distal colon crypt section, and lowered average body weight by 8% compared to controls in CD44-/- mice. Showed no significant effects on small intestinal length, colonic length, villus height, crypt depth, BrdU-positive cell counts, or body weight compared to controls in TLR4-/- mice. |
| Animal Model: |
Lgr5/EGFP C57BL/6J (wild-type, CD44-/-, TLR4-/-, 7 days old at study start) |
| Dosage: |
40 mg/kg |
| Administration: |
i.p.; every other day; 7 days |
| Result: |
Reduced small intestinal crypt fission frequency, reduced colonic crypt fission frequency, decreased percentage of Lgr5+/BrdU+ epithelial cells in nonfissioning crypts, reduced positional epithelial proliferation at crypt base positions 1-4, increased positional apoptosis at crypt positions 1-7, and reduced Paneth cell number per crypt section in wild-type mice. Reduced small intestinal crypt fission frequency, reduced colonic crypt fission frequency, decreased percentage of Lgr5+/BrdU+ epithelial cells in nonfissioning crypts, reduced positional epithelial proliferation at crypt base positions 1-4, showed no significant effect on apoptosis, and showed no significant effect on Paneth cell number in CD44-/- mice. Showed no significant effects on crypt fission frequency, Lgr5+ stem cell proliferation, positional epithelial proliferation, apoptosis, or Paneth cell number compared to controls in TLR4-/- mice. |
| Animal Model: |
BALB/c (female, 6-8 weeks old) |
| Dosage: |
40 µg/ear/injection (complete inhibition); 13.3 µg/ear (partial inhibition); 40 µg/ear (single injection, complete inhibition at 1-2 days pre-DNFB, no inhibition at 3 days pre-DNFB) |
| Administration: |
s.c.; two injections at 24 h and 1 h before DNFB application; single injection at 24 h, 1 day, 2 days, or 3 days before DNFB application |
| Result: |
Prevented DNFB-triggered Langerhans cell migration almost completely (≥80% inhibition across seven independent experiments) with two 40 µg/ear/injection doses. Caused partial inhibition of DNFB-triggered Langerhans cell migration with a single 13.3 µg/ear dose. Caused more prominent inhibition of DNFB-triggered Langerhans cell migration with a single 40 µg/ear dose. Blocked DNFB-triggered Langerhans cell migration completely with a single 40 µg/ear dose administered 1 or 2 days before DNFB application. Lost inhibitory activity for DNFB-triggered Langerhans cell migration with a single 40 µg/ear dose administered 3 days before DNFB application. Showed equivalent inhibitory activity to its His→Ala mutant. Abrogated inhibitory activity in its Trp→Ala mutant form. Did not affect Langerhans cell densities in the absence of DNFB. |
| Animal Model: |
BALB/c (female, 6-8 weeks old) |
| Dosage: |
40 µg/ear/injection |
| Administration: |
s.c.; two injections at 24 h and 1 h before sensitization |
| Result: |
Significantly reduced ear swelling responses to DNFB when sensitized with DNFB on the peptide-injected left ear. Showed comparable ear swelling responses to OX (sensitized on the abdomen) relative to control peptide-treated mice. Significantly reduced swelling responses to OX when sensitized with OX on the left ear. Showed comparable swelling responses to DNFB (sensitized on the abdomen) relative to control peptide-treated mice. Showed similar swelling responses to control peptide-treated mice when resensitized and rechallenged with DNFB, indicating no long-term unresponsiveness. |
| Animal Model: |
BALB/c (female, 6-8 weeks old) |
| Dosage: |
40 µg/ear/injection (s.c.); 1 mg/animal (i.v.); 40 µg/ear (topical) |
| Administration: |
s.c.; two injections at 24 h and 1 h before challenge; i.v.; single injection 1 h before challenge; topical; single application 1 h before challenge after acetone skin barrier disruption |
| Result: |
Caused a significant reduction in ear swelling compared to PBS, control peptide, or Pep-2-treated mice via subcutaneous administration. Caused significant reductions in ear swelling relative to control peptide-treated mice via intravenous and topical administration. Reduced skin edema and leukocyte infiltration compared to controls, with statistically significant decreases in measured ear thickness and infiltrating leukocyte counts. |
| Animal Model: |
BALB/c (female, 6-8 weeks old) |
| Dosage: |
40 µg/ear/injection |
| Administration: |
s.c.; injections on days 0, 1, 3, and 5 |
| Result: |
Significantly reduced ear swelling at every time point tested compared to control peptide-treated mice, with progressive suppression of the chronic inflammatory response. |
| Animal Model: |
C57BL/6 (female, 6-8 weeks old) |
| Dosage: |
500 μg/mouse (co-injection); 40 μg/mouse (days 3 and 6 post-inoculation) |
| Administration: |
s.c.; single co-injection; two additional injections on days 3 and 6 |
| Result: |
Had no significant effect on local tumor growth at the inoculation sites, with tumor size measurements comparable to control groups. |
| Animal Model: |
C57BL/6 (female, 6-8 weeks old) |
| Dosage: |
500 μg/mouse |
| Administration: |
i.v.; single co-injection |
| Result: |
Reduced the number of lung metastatic lesions with statistical significance (P < 0.05) compared to control groups. Prolonged survival significantly (P < 0.01), with a median survival time of 32 days, compared to 26 days for the control peptide group and 25 days for the PBS group. Achieved a 35.1% survival rate (13 of 37 mice) at 48 days post-inoculation, while all PBS-treated mice died by day 28 and only 2 of 30 control peptide-treated mice survived. Resulted in no macroscopically discernible lung metastatic lesions in surviving mice. |
|